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Abstract
Mantle cell lymphomas (MCLs) are the prototypic B-cell non-Hodgkin lymphomas
defined by cyclin D1 gene (CCND1; or other cyclin D family gene) rearrangements.
However, extremely rare cases of diffuse large B-cell lymphomas (DLBCLs) harboring
CCND1 rearrangements, resulting in cyclin D1 protein expression, have also been
reported. In this report, we describe an unusual primary large B-cell lymphoma of
non-germinal center immunophenotype of the central nervous system (CNS) in an
elderly male patient, which was negative for CD5 and SOX11, and exhibited cyclin
D1 expression. Fluorescence in situ hybridization analysis detected IGH-CCND1 and
BCL6 rearrangements. This case may represent the first report of a primary CNS
DLBCL with IGH-CCND1 rearrangement. The clinico-pathologic features that can
help differentiate primary CNS MCL from primary DLBCL of the CNS with IGH-
CCND1 rearrangement are discussed.
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1 | INTRODUCTION
The cell cycle regulator cyclin D1 plays a critical role in the G1-S
cell cycle transition, and its aberrant expression is implicated in the
pathogenesis of a number of hematologic neoplasms, including the
vast majority (>95%) of mantle cell lymphomas (MCLs), a large pro-
portion (40%) of plasma cell neoplasms, and in nearly all hairy cell
leukemias. Since cyclin D1 expression is uncommon in other B-cell
neoplasms, its detection is a valuable tool in discriminating MCL
from other B-cell neoplasms, which can display similar cyto-
morphologic or immunophenotypic features. Importantly, near uni-
form cyclin D1 expression allows distinction of large cell variants
of MCL (pleomorphic and blastoid), which are aggressive forms of
MCL, from diffuse large B-cell lymphomas (DLBCLs), a fraction
of which may exhibit variable degrees of cyclin D1 expression.1,2
The chromosome rearrangement t(11;14)(q13;32), which juxta-
poses the CCND1 region on 11q13 with the immunoglobulin
(Ig) heavy-chain joining region on chromosome 14q32, is a critical
oncogenic driver of MCLs and a subset of plasma cell neoplasms
and the basis of aberrant cyclin D1 expression in these neo-
plasms.3,4 On the other hand, an increase in CCND1 copy number is
considered responsible for cyclin D1 expression in HCL and certain
DLBCLs.1,5 Over the past decade, only rare systemic DLBCLs with
CCND1 rearrangement have been reported, challenging the speci-
ficity of this genomic alteration for MCL.6,7 Here we describe an
unusual case of primary large B-cell central nervous system (CNS)
lymphoma with cyclin D1 expression and t(11;14) (IGH-CCND1) and
review the relevant literature.
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2 | METHODS
2.1 | Morphologic and immunophenotypic
analyses
Formalin-fixed, paraffin embedded (FFPE) sections of core biopsies
were stained with Hematoxylin and Eosin for morphologic assess-
ment. Immunohistochemical (IHC) staining with a comprehensive
panel of antibodies and in situ hybridization staining was performed
as previously described.8
2.2 | Flow cytometry
Multi-color FC analysis was performed on fresh biopsy suspensions as
previously described.9 Multi-color FC antibody panels included B-cell
(CD19, CD20, CD45, surface κ, surface λ, CD10, CD5, CD43, CD103,
CD23, CD38, FMC7, CD11c, CD30, CD34, CD52, IgM, IgD, cytoplas-
mic IgM, cytoplasmic CD79a, and TdT) and plasma cell (CD138,
CD38, CD117, CD56, CD27, CD28, CD45, CD19, CD20, cytoplasmic
κ, and cytoplasmic λ). All antibodies were obtained from BD Biosci-
ences (San Jose, CA). Data was analyzed using FCS Express Version
7 software (De Novo Software, Los Angeles, CA).
2.3 | Fluorescence in situ hybridization analysis
Fluorescence in situ hybridization (FISH) analysis was performed on
FFPE sections according to standard methods using the following pro-
bes: dual fusion probes targeting 14q32/11q13 (IGH/CCND1) and
14q32.2/18q21 (IGH/BCL2) and break apart probes targeting 3q27
(BCL6) and 8q24 (MYC) (Vysis; Abbott Molecular, Des Plaines, IL).
3 | CASE SUMMARY
The patient is an 81-year-old immunocompetent man who presented
with 2 months of cognitive decline and gait instability. An outpatient
evaluation with brain magnetic resonance imaging (MRI) revealed T2/
fluid-attenuated inversion recovery hyperintense focally enhancing
lesions in the right cingulate gyrus and along the right posterior per-
iventricular white matter (Figure 1). His symptoms progressively wors-
ened, and he developed left-sided weakness prompting an admission
to a local hospital, where work-up including contrast-enhanced MRI
of the spine and computerized tomography imaging of the chest and
abdomen were unremarkable. He was transferred to our institution
for further management. His exam was notable for left hemiparesis
and inability to walk independently. A repeat MRI showed marked
increase in size of now homogeneously enhancing right cingulate
gyrus mass, measuring 3 x 4 cm with associated vasogenic edema and
diffusion restriction (Figure 1). Cerebrospinal fluid analysis was signifi-
cant for elevated protein, white blood cells (WBCs) count of 6 (55%
lymphocytes), negative cytology, however, limited flow cytometry
(FC) analysis due to low cellularity. Complete blood count, lactate
dehydrogenase, and beta-2 microglobulin were normal. The patient
underwent stereotactic biopsy of the enlarging mass. Pathology rev-
ealed a large B-cell lymphoma with activated B-cell phenotype and
aberrant cyclin D1 expression, and cytogenetic analysis detected evi-
dence of t(11;14) translocation with CCND1 rearrangement.
In the post-surgical period, staging, including a repeat MRI of the
spine, ophthalmologic evaluation, positron emission tomography scan
of the body, testicular ultrasound, peripheral blood FC, and bone mar-
row biopsy, did not reveal organomegaly, lymphadenopathy, or any
additional sites of disease. Viral studies for human immunodeficiency
virus and Epstein-Barr virus were negative. The patient received high-
dose methotrexate (HD-MTX)-based induction therapy with MT-R
(HD-MTX, temozolomide, rituximab) per Cancer and Leukemia Group
B (CALGB) 50202 protocol.10 He achieved complete clinical and
radiographic response (CR) with a total of seven HD-MTX cycles. MRI
at end of treatment showed a minimal residual patchy enhancement
most consistent with post-operative changes (Figure 1). He then
received consolidation therapy with two cycles of high-dose
cytarabine (3 g/m2) given every 4 weeks. The patient remains in
remission almost a year after CR.
4 | RESULTS AND DISCUSSION
The biopsy sections showed brain parenchyma with infiltrates of
atypical pleomorphic lymphocytes in a perivascular/angiocentric
distribution (Figure 2). The cells are medium to large in size with
coarsely clumped chromatin, variably distinct small nucleoli, and
little eosinophilic cytoplasm. Apoptotic debris was noted and a
few scattered small lymphocytes were present. The atypical cells
were positive for PAX5, BCL6, MUM1, Cyclin D1(strong and dif-
fuse), and BCL2 and negative for CD5, CD10, and SOX11
(Figure 2). The Ki-67 proliferation index was 70%. Approximately
5% of lymphocytes expressed C-MYC. Stains for CD3 and CD5
highlighted small T-cells in the background. In situ hybridization
for EBER was negative. FC detected a population of lambda light
chain-restricted B-cells (85% of gated lymphocytes), which
expressed CD20, CD19, CD79a, HLA-DR, FMC7(bright), CD25,
and IgM and were negative for CD10, CD5, CD38, CD11c,
CD103, CD30, CD43, and IgD.
FISH analysis demonstrated IGH/CCND1 and BCL6 (3q27)
rearrangements in 96% of cells (Figure 3). IGH/BCL2 translocation and
MYC break-apart probes were negative for rearrangement, but
detected multiple copies of IGH, BCL2, and MYC, consistent with near
tetraploidy (polyploidy). The bone marrow aspirate showed a normal
karyotype with no evidence of CCND1 rearrangement by FISH
analysis.
Thus, the patient's large B-cell lymphoma exhibited a non-
germinal center (GC) phenotype, with strong and diffuse cyclin D1
expression and an absence of extra-CNS disease. This lymphoma
raises the challenging differential diagnosis of an unusual aggressive
variant of MCL with a primary CNS presentation vs a primary CNS
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DLBCL with cyclin D1 expression associated with IGH-CCND1
rearrangement.
Primary central nervous system lymphomas (PCNSLs) account for
approximately 4% of all brain tumors and less than 1% of all non-
Hodgkin lymphomas.11,12 They are most commonly represented by
DLBCL of non-GC or activated B-cell phenotype (express BCL6 and
MUM1), whereas CD10 expression is rare, and the vast majority
(>80%) are double expressors of BCL2 and MYC.13 The frequency of
BCL6 rearrangements (17%) is considerably less common than in
DLBCL arising outside the CNS, while rearrangements of MYC and
BCL2 are essentially not seen.13,14 Most CNS DLBCLs demonstrate
evidence of genomic instability and numerous copy-number alter-
ations. This is likely the result of frequent deletion of CDKN2A and/or
FHIT, which occur far more often in CNS DLBCL than in ABC-type
DLBCL elsewhere.13 Additional events include amplification of
NFKBIZ on 3q12.3, gain of 18q (leading to BCL2 overexpression), and
amplification of 9p24, including CD274 and PDCD1LG2.13 Deletions
of HLA class II genes on 6p21 are also seen in approximately 75% of
CNS DLBCLs, further contributing to escape of immune
surveillance.13
Secondary CNS involvement by MCL is uncommon, reported
rates vary widely from 4% to 26%, and typically occurs late in the
course of the disease.15 Rare cases of PCNSLs with Cyclin D1 expres-
sion and/or rearrangement have been reported in the literature. In
one case, both IGH-CCND1 and IGH-MYC rearrangements were
detected by FISH analysis.16 The lymphoma was composed of
medium- to large-sized B-cells that expressed CD20, CD5(weak),
CD10, Cyclin D1, and BCL2 and had a high Ki-67 proliferation
index.16 The authors considered it to be an example of “double-hit”
lymphoma with Burkitt and MCL characteristics. Two other cases of
F IGURE 1 MRI images. Post-contrast T1-weighted MRI images demonstrating (a) small enhancing mass in the right cingulate gyrus at time of
presentation. (b) Significant increase in size of the lesion 4 weeks later. (c) Partial response after first cycle of methotrexate, rituximab,
temozolomide. (d) Complete response following treatment completion
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primary CNS MCLs did not document cytogenetic analysis.17,18 How-
ever, the immunophenotype of one case (CD19+, CD20+, CD79a+,
CD5+, and Cyclin D1+ and an absence of CD10, CD11c, and CD23
expression) was consistent with classic MCL, but the
immunophenotype of the other lymphoma diagnosed as “MCL” was
only partially provided. Classic MCL is usually positive for CD20, CD5,
IgM, IgD, CD38, CD43, and Cyclin D1. Expression of CD10 (2.4-6.6%)
and BCL6 (10-12%) is typically absent in MCL, while lack of CD5
(2-11%) or Cyclin D1 (6%) expression is uncommon.19-22 SOX11
nuclear expression has been shown to be a highly specific marker for
MCL (>93%), since it is not expressed in other B-lymphoid neoplasms,
with the exception of lymphoblastic lymphoma, and some Burkitt's
lymphomas.23,24The current B-cell lymphoma was negative for CD5,
CD10, CD38, CD43, and SOX11 (Figure 2). This immunophenotype
and absence of systemic disease argue against the diagnosis of MCL,
though the possibility of an unusual pleomorphic variant of MCL pre-
senting as PCNSL cannot be ruled out entirely.
Aberrant expression of Cyclin D1 in systemic DLBCL is uncom-
mon, but has a frequency of up to 15% in some case series.1 Cyclin
D1+ DLBCL can exhibit either GC or non-GC B-cell phenotype, but
invariably lack CD5 and SOX11 expression.1,25 Chromosome
rearrangement of the CCND1 gene is not typically detected in such
lymphomas, but an increase in CCND1 copy number has been
described.1,25 To date, only four examples of systemic DLBCL with
CCND1 rearrangement have been reported in the literature.6,7
Juskevicius et al. reported two systemic DLBCLs, one harboring
t(11;14)(q13;q32) and the other with a complex t(4;11;14)(q22;q13;
q32) translocation with features intermediate between MCL and
DLBCL.7 FISH analyses for MYC and BCL2 rearrangements were nega-
tive, while BCL6 abnormalities were not reported.7 The cases reported
by Al-Kawaaz et al. comprised two systemic DLBCLs harboring
t(11;14) in patients with diffuse lymphadenopathy.6 The authors
found concurrent BCL6 rearrangements in both cases, and since BCL6
rearrangement is a frequent genetic aberration in non-GCB subtype
F IGURE 2 Morphology and immunohistochemical stains. (a) 20x and (b) 40x H&E staining showing diffuse, medium to large-sized
pleomorphic lymphoid cells with a perivascular/angiocentric distribution. Lymphoma cells are positive for BCL6 (c), MUM1 (d), BCL2 (e) and
Cyclin D1 (f) (images are 10x)
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DLBCL (detected in 72.7% of this study's non-GCB cohort), this fea-
ture was considered supportive of DLBCL in their cases.6 As men-
tioned above, BCL6 rearrangements are less frequent events in
primary CNS DLBCL, but are rarely seen in MCL (4/315 cases of MCL
in one study26). The CNS large B-cell lymphoma in our patient has
immunophenotypic and cytogenetic similarities to these rare systemic
DLBCLs, as well as near tetraploidy genotype (multiple copies of IGH
(Figure 3), BCL2 and MYC detected by FISH analysis), therefore may
represent the first documentation of a primary DLBCL of the CNS
with CCND1 rearrangement.
Primary CNS DLBCL typically shows activating mutations in
MYD88 and CD79B and inactivating mutations in CARD11 and
TNFAIP3.13 This somatic mutation profile is different from the somatic
mutation landscape of MCL in general, which includes most frequently
mutations of ATM, CCND1, TP53, genes encoding the anti-apoptotic
protein BIRC3 and Toll-like receptor 2 (TLR2) and the chromatin modi-
fiers WHSC1, MLL2, and MEF2B.27 Given the differences in the
somatic mutation profiles between primary CNS DLBCL and MCL,
targeted molecular studies could have contributed to further resolve
the differential diagnosis in our case; however, molecular studies
could not be performed due to exhaustion of biopsy material.
Regardless of the pathologic classification of this primary CNS
large B-cell lymphoma and despite the aberrant Cyclin D1 expression
and underlying t(11;14), the patient was treated with a regimen typi-
cally used for primary CNS DLBCL and achieved CR. While HD-MTX
and rituximab-based therapy can be used in MCL, the rapidity, extent,
and duration of treatment response seen in our patient further
support the diagnosis of primary CNS DLBCL rather than MCL involv-
ing the CNS.28
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